Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
Open Access
- 26 September 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 76 (5), 997-1004
- https://doi.org/10.1007/s00280-015-2873-x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic MelanomaJournal of Clinical Oncology, 2015
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated MelanomaNew England Journal of Medicine, 2015
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialThe Lancet Oncology, 2015
- Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)Annals Of Oncology, 2013
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T CellsCancer Immunology Research, 2013
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodiesThe Journal of Experimental Medicine, 2009
- Ipilimumab: controversies in its development, utility and autoimmune adverse eventsCancer Immunology, Immunotherapy, 2009
- Principles and use of anti-CTLA4 antibody in human cancer immunotherapyCurrent Opinion in Immunology, 2006
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996